As shown in Figure 1(a), compared with normal controls, EIF4G2 was markedly upregulated in a variety of cancers, including esophageal carcinoma (ESCA), cholangiocarcinoma (CHOL), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD). This evidence concerns the gene EIF4G2 and cholangiocarcinoma.